沙库巴曲缬沙坦治疗HFrEF患者的临床疗效及对患者心功能、生活质量的影响

doi:10.3969/j.issn.1671-7171.2025.09.016

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1239 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical efficacy of sacubitril/valsartan in the treatment of patients with heart failure with reduced ejection fraction(HFrEF) and its impact on patients' cardiac function and quality of life.【Methods】 The clinical data of 90 HFrEF patients admitted to Xuchang Central Hospital from May 2023 to May 2024 were selected. According to different treatment regimens, the patients were divided into the control group(routine anti-heart failure treatment) and the observation group(valsartan was discontinued on the basis of the control group, and sacubitril/valsartan sodium tablets were added), with 45 cases in each group. The clinical efficacy, cardiac function indicators [left ventricular ejection fraction(LVEF), left atrial diameter(LAD), left ventricular end-diastolic diameter(LVEDD)], ventricular remodeling indicators [interventricular septal thickness(IVST), left ventricular posterior wall thickness(LVPWT), left ventricular mass index(LVMI)], laboratory indicators [high-sensitivity C-reactive protein(hs-CRP), B-type natriuretic peptide(BNP)], quality of life [Minnesota Living with Heart Failure Questionnaire(MLHFQ) score] and exercise tolerance [6-minute walk distance(6MWD)] were compared between the two groups.【Results】 The clinical effective rate of the observation group was higher than that of the control group, with a statistically significant difference(P<0.05). After treatment, the LVEF of both groups was higher than that before treatment, while LAD and LVEDD were lower than those before treatment; the LVEF of the observation group was higher than that of the control group, and LAD and LVEDD were lower than those of the control group, with statistically significant differences(P<0.05). After treatment, the IVST, LVPWT and LVMI of both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences(P<0.05). After treatment, the serum levels of hs-CRP and BNP in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences(P<0.05). After treatment, the MLHFQ scores of both groups were lower than those before treatment, and 6MWD was longer than that before treatment; the MLHFQ score of the observation group was lower than that of the control group, and 6MWD was longer than that of the control group, with statistically significant differences(P<0.05).【Conclusion】 Sacubitril/valsartan sodium tablets have good clinical efficacy in the treatment of HFrEF patients. They can effectively reduce the cardiac load of patients, inhibit pathological ventricular remodeling, and improve patients' quality of life and exercise tolerance.

Key words： Heart Failure Valsartan Heart Function Tests Quality of Life

Received: 05 March 2025

PACS:

R541.61

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Xiaojing
	ZHANG Qingde

Cite this article:

YANG Xiaojing,ZHANG Qingde. The Clinical Efficacy of Sacubitril/Valsartan in the Treatment of Patients with HFrEF and its Impact on Cardiac Function and Quality of Life[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1545-1548.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.09.016 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I9/1545

[1] 许丁,赵慧慧,周淑文,等. 沙库巴曲缬沙坦与缬沙坦治疗射血分数降低的心力衰竭的临床疗效及其对血清肿瘤坏死因子α、半乳糖凝集素3、基质金属蛋白酶9水平的影响[J].实用心脑肺血管病杂志,2023,31(1):107-111.
[2] 苏虹,李仕林,严定一,等. 沙库巴曲缬沙坦钠片治疗慢性心力衰竭的疗效及对血清CysC、BNP水平的影响[J].检验医学与临床,2024,21(14):2066-2070.
[3] 杜建平,杨霄羽,姚朱华.“新四联”引领下射血分数降低的心力衰竭的新型多靶点药物治疗进展[J].心血管病学进展,2025,46(8):677-681.
[4] 李旭,赵兴胜.射血分数降低的心力衰竭药物治疗进展[J].国际心血管病杂志,2025,52(1):13-16.
[5] 中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等. 中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志,2024,52(3):235-275.
[6] YANG Y J,HUO Y,XU Y W,et al.Percutaneous ventricular restoration therapy using the parachute device in Chinese patients with ischemic heart failure:three-month primary end-point results of PARACHUTE China study[J].Chin Med J(Engl),2016,129(17):2058-2062.
[7] 王义为,金屏,翟蒙恩,等. D-shant心房分流器用于射血分数降低的心力衰竭患者短期结果[J].中国介入心脏病学杂志,2024,32(8):434-442.
[8] 顾崇怀,项学军,郑元喜,等. 达格列净对接受冠状动脉介入治疗的伴有射血分数降低的心力衰竭合并2型糖尿病老年病人疗效观察[J].实用老年医学,2024,38(10):1025-1029.
[9] 张先林,路桥,李会龙,等. 沙库巴曲缬沙坩联合达格列净与射血分数减低的心力衰竭临床疗效及预后的相关性[J].中华急诊医学杂志,2022,31(10):1396-1401.
[10] 王清辉. 沙库巴曲缬沙坦治疗射血分数降低的心力衰竭的临床疗效观察[J].中西医结合心脑血管病杂志,2024,22(15):2836.
[11] 骆晗,欧阳泽伟. SDC1、NT-proBNP在慢性心力衰竭患者血清中的表达水平及其临床意义[J].医学临床研究,2022,39(5):667-670.
[12] 杨淑,叶城麟,左宝功. 不同类型心力衰竭患者发生冠心病的风险及预后观察[J].医学临床研究,2023,40(7):1095-1097.
[13] 杨萍,刘培晶,丁澍,等.hs-cTnT、sST2联合BNP评估射血分数降低的慢性心力衰竭的临床意义[J].江苏大学学报(医学版),2019,29(5):414-418.